Nora Luo focuses on patent prosecution and strategic intellectual property counseling in the biotechnology and pharmaceutical industries. Her practice includes preparation and prosecution of U.S. and international patent applications, patent portfolio management, due diligence evaluations, freedom-to-operate analyses, patentability evaluations, and inter partes review proceedings.
Nora has worked with established companies, start-ups, and research institutions. She has experience with a wide range of technologies, including immunotherapy (for example, antibodies, antibody drug conjugates, vaccines, cell-based therapies, CAR-T cell technology, immune checkpoint modulators), gene therapy, CRISPR technology, mRNA delivery, mRNA-based therapy, lipid nanoparticles, viral vector-based gene delivery system (for example, AAV [adeno-associated virus]), antibody engineering, RNA splicing, cancer therapeutics, virology, stem cells, neurological disorder therapeutics, high-throughput screening, genomics, diagnostic assays, anti-aging therapeutics, and small molecule pharmaceuticals.
Nora holds a Ph.D. in molecular biology from Princeton University. While at Princeton, she was awarded the American Society for Cell Biology Norton B. Gilula Award and was the recipient of the National Institute of Health Fellowship. Prior to joining Jones Day, Nora was a Damon Runyon Cancer Research fellow at The Rockefeller University. Her scientific work has been published in a number of peer-reviewed journals, including Cell and Science, and was featured in The New York Times and Nature.
Expérience
- Fordham University (J.D. magna cum laude 2019; Ruth Whitehead Whaley Scholar); Princeton University (Ph.D. in Molecular Biology 2012); Fudan University (B.S. in Biological Sciences 2005)
- New York and registered to practice before the United States Patent and Trademark Office
- Mandarin